Rhythm Pharmaceuticals (RYTM) Reports In-Line Q4 EPS, provides guidance

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q4 EPS of ($0.70), in-line with the analyst estimate of ($0.70). Revenue for the quarter came in at $24.2 million versus the consensus estimate of $25.63 million.
Guidance:
For the year ended December 2023, the Company had GAAP total operating expenses of $261.8 million.
The Company today reported non-GAAP Operating Expenses for the year ended December 31, 2023 of $219.9 million, which is derived from GAAP total costs and expenses of $261.8 million less $9.3 million in cost of sales and less $32.6 million in stock-based compensation.
For the year ending December 31, 2024, Rhythm anticipates approximately $250 million to $270 million in Non-GAAP Operating Expenses.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• RH (RH) Tops Q1 EPS by 12c